Pentixapharm Holding AG (von NuWays AG): BUY 15.07.2026, 09:00 Uhr von dpa-AFX Jetzt kommentieren: 0

Original-Research: Pentixapharm Holding AG - from NuWays AG



15.07.2026 / 09:00 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS
Group.
The issuer is solely responsible for the content of this research. The
result of this research does not constitute investment advice or an
invitation to conclude certain stock exchange transactions.



---------------------------------------------------------------------------



Classification of NuWays AG to Pentixapharm Holding AG



     Company Name:                Pentixapharm Holding AG
     ISIN:                        DE000A40AEG0



     Reason for the research:     Initiation
     Recommendation:              BUY
     Target price:                EUR 7.2
     Target price on sight of:    12 months
     Last rating change:
     Analyst:                     Simon Keller



A major diagnostic market opening. Pentixapharm is the way to play it.



In July 2025, Endocrine Society delivered the most consequential catalyst
for Pentixapharm's late-stage diagnostic asset PentixaFor. Recognising the
structural under-diagnosis of primary aldosteronism (PA), updated guidelines
now recommend universal screening of all patients with hypertension, rather
than restricting testing to traditionally defined high-risk groups. PA is
dangerous if missed, but very treatable when detected early. Following
detection, patients are subtyped as curable by a single surgery or as
victims of lifelong medication. This important subtyping "tool" exists; it's
called adrenal vein sampling (AVS).



But here's the catch: this solution is also part of the problem. AVS is
invasive, technically challenging and can yield variable results depending
on operator skill. Neither physicians, nor patients find it appealing.
Together with historically sparce screening under the old guidelines is
exactly why it is rarely used. The result: millions of eligible patients
never get to the cure and spend a fortune on lifelong medications. However,
the two major adoption bottlenecks - low screening rates and the limited
appeal of subtyping - are on the verge of breaking.



Enter PentixaFor: a simple, non-invasive and easy to scale PET scan.
Unsurprisingly, 96% of Phase 2 patients preferred this method over AVS. Now,
it is Phase 3-ready, backed by substantial prior clinical evidence and
strong regulatory support, including FDA Fast Track and EMA PRIME status. To
comfortably proceed with the trial, the company just announced a rights
issuance targeting c. EUR 20m in proceeds at EUR 1.85/share.



The recommended blanket screening approach under the new guidelines and the
emergence of a scalable subtyping alternative are set to open the floodgates
for broader patient screening. In fact, the annual pool of patients eligible
for subtyping is seen to expand by more than 8x to c. 561,000 patients in
the US and EU, driven by a much wider eligibility and high screening
frequency (eNuW).



The combination of a large addressable market and favorable economics of a
first-in-class diagnostic in an unmet need creates a highly compelling
commercial opportunity. We estimate peak sales at EUR >1bn by 2039.



Our risk-adjusted NPV-based valuation yields a PT of EUR 7.20, implying c.
270% upside. BUY.





You can download the research here:
https://nwr.eqs-cockpit.com/fncls2.ssx?fn=redirect&u=1dd1d0399366408600f180294176cc0e
For additional information visit our website:
https://www.nuways-ag.com/research



Contact for questions:
NuWays AG - Equity Research
Web: www.nuways-ag.com
Email: research@nuways-ag.com
LinkedIn: https://www.linkedin.com/company/nuwaysag
Adresse: Mittelweg 16-17, 20148 Hamburg, Germany
++++++++++
Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss
bestimmter Börsengeschäfte.
Offenlegung möglicher Interessenkonflikte nach § 85 WpHG beim oben
analysierten Unternehmen befindet sich in der vollständigen Analyse.
++++++++++



---------------------------------------------------------------------------



The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
View original content:
https://eqs-news.com/?origin_id=16a26863-8016-11f1-8534-027f3c38b923&lang=en



---------------------------------------------------------------------------



2365974 15.07.2026 CET/CEST